The fund employs a passive investment strategy, aiming to replicate the total return performance of its benchmark index. This index is rule-based, comprising equities or their corresponding depositary receipts from companies involved in the entire spectrum of DNA Modification Technology, including its invention, advancement, production, operation, provision, distribution, ownership, maintenance, licensing, leasing, or franchising. A minimum of 80% of the fund's net assets are dedicated to enterprises focused on DNA Modification Technology. This is a non-diversified fund.

CRISPR Therapeutics AG

Beam Therapeutics Inc.

Thermo Fisher Scientific Inc.

Intellia Therapeutics, Inc.

Prime Medicine, Inc.

Editas Medicine, Inc.

Caribou Biosciences, Inc.

Verve Therapeutics, Inc.

Poseida Therapeutics, Inc.

AbbVie Inc.

Healthcare

Kelly CRISPR & Gene Editing Technology ETF

XDNA Holdings & Sector Breakdown

XDNA Holdings & Sector Breakdown